Repertoire Immune Medicines signed a high‑value partnership with Eli Lilly to develop tolerizing therapies for multiple autoimmune diseases. The deal includes an $85 million upfront payment, up to $1.84 billion in development and commercial milestones, plus tiered royalties, marking Repertoire’s largest collaboration to date and external validation of its Decode platform. Repertoire will work with Lilly on program discovery and early development; Lilly will fund later‑stage work and commercialization. The partnership follows other big pharma collaborations Repertoire has secured and underscores a growing strategic interest in immune‑tolerance approaches for autoimmunity. Sources include company press releases and industry coverage; the transaction signals continued appetite from top‑tier pharma to buy platform‑level immune insight and convert it into disease‑specific programs.